Chemotherapy-Induced Myelosuppression and Anxiety, Depression, and Sleep Quality Among Family Caregivers of Patients With Cancer: A Patient–Caregiver Paired Cohort Study
Objective To investigate the association between chemotherapy-induced myelosuppression and anxiety, depression, and sleep quality among family caregivers of patients with cancer, and to identify factors associated with these psychological and sleep outcomes. Methods A patient–caregiver paired cohort study was conducted. Patient demographic and clinical characteristics were collected before chemotherapy or within 48 h of hospital admission. Complete blood counts were reassessed 7–14 days after completion of chemotherapy. Myelosuppression was determined based on the lowest recorded white blood cell count, hemoglobin level, and platelet count during this observation period. Patient–caregiver pairs were classified into the no-myelosuppression (No-BMS) group or the myelosuppression (BMS) group, and myelosuppression severity was graded from 0 to 4 according to World Health Organization criteria. During the same observation window, family caregivers completed the Hospital Anxiety and Depression Scale (HADS) and the Pittsburgh Sleep Quality Index (PSQI). Between-group comparisons, correlation analyses, and multivariable linear regression analyses were performed to examine the associations between myelosuppression and caregivers’ psychological and sleep outcomes. Results A total of 634 patient–caregiver pairs were included in the analysis, comprising 279 pairs in the No-BMS group and 355 in the BMS group. The incidence of myelosuppression was 55.99%. Family caregivers in the BMS group had higher HADS anxiety, HADS depression, and PSQI scores than those in the No-BMS group. Linear regression analyses demonstrated that chemotherapy-induced myelosuppression was significantly associated with higher caregiver anxiety, depression, and PSQI scores (all P < 0.001). Significant differences in HADS anxiety, HADS depression, and PSQI scores were also observed across different grades of myelosuppression, with all three scores showing an overall upward trend as myelosuppression severity increased. Multivariable analyses further identified several patient- and caregiver-related factors associated with caregivers’ psychological and sleep outcomes, including a history of myelosuppression, patient performance status, pathological diagnosis, patient age, caregiver educational level, caregiver sex, and caregiver–patient relationship. Conclusion Chemotherapy-induced myelosuppression was associated with greater anxiety and depression and poorer sleep quality among family caregivers of patients with cancer. During the period of increased risk for post-chemotherapy myelosuppression, clinical care should incorporate concurrent assessment of caregivers’ psychological well-being and sleep quality, with risk-stratified supportive interventions provided to caregivers at higher risk.
Authors
- Lingling Xie
- Xiaozhen Luo
- Jiang Zhu
- Lili Yang
- Jie Xian
- Yuhong Zhou
- Jurong Liao
- Jing Wang
- Jing Chen
- Xin Yang
Institutions
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-20
- DOI
- https://doi.org/10.21203/rs.3.rs-11179550/v1
- Primary Topic
- Cancer survivorship and care
- Type
- preprint